which glp 1 agonists are approved for weight loss Market Overview: GLP-1 and the Obesity Market | Blog GLP-1R Agonists for Weight Loss

An observational study of cardiovascular outcomes of tirzepatide vs glucagon-like peptide-1 receptor agonists

Evidence demonstrates that acute glucose fluctuation forms the stress that alters microglial activity (eg, inflammatory activation or self-degradation), which may be one of the mechanisms of cognitive deterioration in diabetic patients

Xie Y, Bowe B, Xian H, Loux T, McGill JB, Al-Aly Z

Post-hoc analyses of weight loss trials provide additional context

They must either have: BMI of at least 35 BMI of at least 30 plus a history of heart failure, uncontrolled hypertension or chronic kidney disease BMI of at least 27 plus prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease